The role of PD-L1 in EGFR-mutant non-small cell lung cancer.

• Tác giả: Wentao Gao, Lingling Wang, Yanyan Zhao, Lucheng Zhu
• Ngôn ngữ: eng
• Thông tin xuất bản: United States : Discover oncology , 2025
• Bộ sưu tập: NCBI
• ID: 703703

Tóm tắt

Lung cancer remains the leading cause of cancer-related deaths globally. In China, nearly half of non-small cell lung cancer (NSCLC) patients carry epidermal growth factor receptor (EGFR) mutations. EGFR tyrosine kinase inhibitors (EGFR-TKIs) have significantly improved the prognosis for patients with EGFR mutations and are considered the preferred treatment for these individuals. Programmed death-ligand 1 (PD-L1) expression levels are now widely used as a biomarker to predict the effectiveness of PD-1/PD-L1 immunotherapy in NSCLC. Additionally, the impact of PD-L1 expression on the efficacy of EGFR-TKIs has garnered considerable attention from researchers. This review explores recent studies on the epidemiology and clinical outcomes associated with PD-L1 in NSCLC patients harboring driver gene mutations.